A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Nature Communications

Topics

Biology

Biochemistry

Medicine

Internal Medicine

Infectious Diseases

Show all topics

DOI

10.1038/s41467-024-49458-9

License

CC-BY

Other Formats

PDF